CVR number 43078046
Industry 72.1100 Research and experimental development on biotechnology

MyoPax Denmark ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.2% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 0.0% 18.1% 17.8%  
Credit score (0-100)  0 0 0 7 8  
Credit rating  N/A N/A N/A B B  
Credit limit (kDKK)  0.0 0.0 0.0 -0.0 -0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 0.0 -1,832 -4,853  
EBITDA  0.0 0.0 0.0 -2,157 -5,967  
EBIT  0.0 0.0 0.0 -2,157 -5,967  
Pre-tax profit (PTP)  0.0 0.0 0.0 -2,251.0 -6,340.3  
Net earnings  0.0 0.0 0.0 -1,988.0 -5,320.3  
Pre-tax profit without non-rec. items  0.0 0.0 0.0 -2,251 -6,340  
 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 0.0 -1,948 -7,268  
Interest-bearing liabilities  0.0 0.0 0.0 4,089 10,462  
Balance sheet total (assets)  0.0 0.0 0.0 2,565 3,351  
Net Debt  0.0 0.0 0.0 1,886 8,187  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 -1,832 -4,853  
Gross profit growth  0.0% 0.0% 0.0% 0.0% -164.9%  
Employees  0 0 0 1 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 100.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 0 2,565 3,351  
Balance sheet change%  0.0% 0.0% 0.0% 0.0% 30.6%  
Added value  0.0 0.0 0.0 -2,157.0 -5,966.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 0.0 -1.0 -2.0  

Profitability 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% 117.7% 123.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 0.0% -47.8% -78.9%  
ROI %  0.0% 0.0% 0.0% -52.8% -82.0%  
ROE %  0.0% 0.0% 0.0% -77.5% -179.9%  

Solidity 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 0.0% -43.2% -68.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% -87.4% -137.2%  
Gearing %  0.0% 0.0% 0.0% -209.9% -143.9%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 4.6% 5.1%  

Liquidity 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 6.0 21.3  
Current Ratio  0.0 0.0 0.0 6.0 21.3  
Cash and cash equivalent  0.0 0.0 0.0 2,203.0 2,275.3  

Capital use efficiency 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 0.0 2,141.0 3,193.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 -2,157 -2,983  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -2,157 -2,983  
EBIT / employee  0 0 0 -2,157 -2,983  
Net earnings / employee  0 0 0 -1,988 -2,660